Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 1505 results for patients and public

  1. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    In development Reference number: GID-TA11336 Expected publication date: TBC

  2. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development Reference number: GID-TA11343 Expected publication date: TBC

  3. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

  4. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    In development Reference number: GID-TA11497 Expected publication date: TBC

  5. Artificial intelligence software to help detect and characterise colorectal polyps

    In development Reference number: GID-DG10118 Expected publication date: TBC

  6. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  7. The geko device for reducing the risk of venous thromboembolism (HTG344)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

  8. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

    Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.

  9. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (IPG523)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

  10. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

  11. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries (IPG762)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. This involves keyhole abdominal surgery. The aim is to stimulate and possibly strengthen the diaphragm to help people breathe without a ventilator.

  12. Open prenatal repair for open neural tube defects in the fetus (IPG668)

    Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus. This involves open surgery through the woman’s abdomen to close the gap in the baby’s spine.

  13. Focal resurfacing implants to treat articular cartilage damage in the knee (IPG734)

    Evidence-based recommendations on focal resurfacing implants to treat articular cartilage damage in the knee in adults. This involves replacing the damaged area with an artificial implant.

  14. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

  15. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making